US 2022/0175672 A1Published application

Compositions and methods for sustained drug release from an injectable hydrogel

OwnerGregory Grover, Kevin Eisenfratsinventors

Life of this patent

Estimating the term…

Loading patent…

Abstract

Compositions, devices and methods of using one or more hydrogel for contraception as well as localized, sustained delivery of drugs are disclosed. Device (e.g., hydrogel) embodiments are easily injectable, have a quick gelation rate, are highly durable, and are capable of lasting greater than 3 months in vivo. The devices/hydrogel may be used for occlusion of a bodily duct, such as the vas deferens and/or fallopian tubes, for male and female contraception, respectively. Once implanted, the device/hydrogel is able to release one or more drugs, such as small molecules or biologics, indirectly, systemically, and/or directly to the site of interest over a sustained period of time, such as for prevention and/or treatment of STIs.

Claims18

Dependent claims

A composition, comprising:

a first component and a second component, the first component formulated to be crosslinked with the second component to form a hydrogel;
wherein the first component is a multi-arm polyethylene glycol terminated with a thiol and the second component is a multi-arm polyethylene glycol terminated with a maleimide;
the first component and the second component being formulated to have an initial storage modulus (initial G′) and an initial loss modulus (initial G″) when the first component and the second component are initially combined, a ratio of the initial G″ to the initial G′ being between about 5 and about 100;
and
the first component and the second component being formulated to have a gelation storage modulus (gelation G′) and a gelation loss modulus (gelation G″) at a gelation time after the first component and the second component are combined, a ratio of the gelation G″ to the gelation G′ being less than about 1, the gelation time being less than about 120 seconds.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/677,295Filed 22 Feb 2022
Priority: 22 Aug 2019
Published: 9 Jun 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 9/06
Medicinal preparations characterised by special physical form: ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
A61K 9/0024
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in…
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/568
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in positions 10 and 13 by a chain having at least one…

Family

Application62/890,409Us provisional application · filed 22 Aug 2019
Application63/024,628Us provisional application · filed 14 May 2020
Application63/056,124Us provisional application · filed 24 Jul 2020
Application17/677,295Continuation
US 2022/0175672 A1This patent

From the US filing history. Foreign family members aren’t listed.